Biocon

History

Year	Detail
1978	Biocon commenced operations as a joint venture between Ms. Kiran Mazumdar-Shaw and Biocon Biochemicals Limited, an Ireland-based multinational. Biocon began manufacturing and exporting Papain, a plant enzyme, and Isinglass, a marine hydrocolloid.
1982	BioChemizyme India was incorporated to focus on research and development concerning enzymes.
1989	Unilever plc. Acquired Biocon Biochemicals Ltd. in Ireland and merged it with its subsidiary, Quest International.
1995	Biocon Quest India Limited was established in August 1996, with Biocon and Unilever acquiring a 50% stake each. BQIL commenced manufacturing operations in September 1996.
2000	Biocon acquired the entire shareholding of BioChemizyme India, Biocon Quest India Limited, and Helix Biotech Limited from Glentec International, Ms. Kiran Mazumdar-Shaw, and others in exchange for the issue of shares by Biocon. Biocon became an independent entity, and Glentec International acquired a majority stake (approx. 64%) in Syngene as part of a fresh issue of shares.
2000	Clinigene was incorporated to conduct longitudinal clinical studies in select disease segments as a wholly owned subsidiary of Biocon.
2002	Biocon acquired 99.99% of Syngene from its other shareholders, including ICICI Venture and its affiliate funds. Thus, Syngene became a 99.99% subsidiary of Biocon Limited.
2003	Biocon Biopharmaceuticals Private Limited was incorporated to manufacture and market a select range of biotechnology-based life-saving drugs as a 51:49 joint venture with the Cuban Centre of Molecular Immunology and Biocon.
2004	Biocon Limited and North Carolina's Nobex Corporation collaborated to develop an oral Insulin product for treating Diabetes globally.
2004	Biocon Limited and Vaccinex, Inc. partnered to discover and co-develop at least four therapeutic antibody products.
2005	Biocon Limited signed a commercial agreement to supply insulin API in Asia, Africa, and the Middle East.
2006	Biocon announced a licensing agreement with Bayer HealthCare (BHC) for the exclusive marketing and trademark rights to INSUGEN in the Chinese market.
2007	Biocon and Abu Dhabi-based pharmaceutical company Neopharma Joint ventured to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council).
2009	Biocon's Syngene partners with Sapient Discovery to expand integrated drug discovery offerings.
2013	Biocon enhances its partnership with Mylan through strategic collaboration for insulin products.
2013	Biocon and Quark Pharmaceuticals collaborated to develop novel siRNA-based therapeutics.
2015	NeoBiocon partnered with Novartis to offer vildagliptin for people with diabetes in the UAE.
2020	Biocon Biologics and Voluntis collaborated to develop and distribute digital therapeutics supporting people with diabetes on biologics therapy.